Cancer

Why some brain tumors respond to immunotherapy

Columbia researchers have learned why some glioblastomas—the most common type of brain cancer—respond to immunotherapy. The findings could help identify patients who are most likely to benefit from treatment with immunotherapy ...

Cancer

Neoadjuvant PD-1 blockade seems effective in glioblastoma

(HealthDay)—Neoadjuvant administration of programmed cell death protein 1 (PD-1) blockade seems to enhance local and systemic antitumor immune response in glioblastoma, according to a study published online Feb. 11 in Nature ...

Cancer

Research to advance cancer therapy

Research led by Suresh Alahari, Ph.D., the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, has found a new role for a protein discovered by his lab in preventing the ...

Cancer

Tissue stiffness is a "mosh pit" where cancer cells thrive

Imagine being at a packed concert hall with a mosh pit full of dancers creating a wall against outsiders. When targeted drugs try to make their way toward a pancreas tumor, they encounter a similar obstacle in stiff tissue ...

page 1 from 11